Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Hello. At this time, I would like to welcome everyone to the Exact Sciences. Third quarter, 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to Erik ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

We generated a record $113 million in free cash flow ... revenue due to the normal 30-day timing between a Cologuard order and a completed test. Second, disruption from Hurricane Helene and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Highlights:,Cologuard Plus™ outperforms other noninvasive screening tests in life-years gained and reduces the need for ...

The Cologuard Plus test detects cancers and precancerous polyps with even ... adjusted other operating income (loss), adjusted operating income (loss), and free cash flow. Core revenue is calculated ...

Free Cash Flow: $113 million ... with expectations for increased returns in the near and long term. The growth in Cologuard testing frequency among the expanding provider base was disappointing, ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening ...